<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Effect of metformin on thyroid cancer risk in patients with acromegaly: a preliminary observational study

Loading...
Thumbnail Image

Departments

School / College / Institute

Item type:Organizational Unit,

Program

Organization Authors

Co-Authors

Sulu, Cem

Guzel, Suleyman Sami

Tay, Kubilay

Sahin, Serdar

Durcan, Emre

Ozkaya, Hande Mefkure

Kadioglu, Pinar

Date

Language

Embargo Status

N/A

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Purpose: To evaluate the role of metformin on thyroid cancer risk in patients with acromegaly. Methods: Medical charts of 534 patients with acromegaly that were followed-up between 1983 and 2019 were reviewed. Patients with follow-up duration at least 6 months were included. Cohort entry was defined as first visit date. The date of each case's thyroid cancer diagnosis was defined as index date. Patients were followed until the index date, death, or last visit date, whichever came first. Nested case-control study design was selected to evaluate the association between metformin and the thyroid cancer risk in patients with acromegaly. Results: 291 patients with acromegaly were included into final analysis. The mean age at acromegaly diagnosis was 42.3 +/- 1.3 years. The median follow-up duration was 76 [34-132] months. Among 291 patients, 13 patients (4.5%) had thyroid cancer. Thirty-one percent (n = 92) of the patients used metformin for 6 months or longer. One standard deviation (SD) increase in average growth hormone increased the odds of having thyroid cancer by 1.164 folds (p = 0.017). One SD increase of the average insulin-like growth factor 1 to upper limit of normal ratio increased the odds of having thyroid cancer by 1.201 folds (p = 0.004). If a patient used metformin for at least 6 months, the odds to have thyroid cancer was decreased, multiplied by 0.62 with a 95% confidence interval of [0.47, 0.83] (p = 0.0013). The risk of thyroid cancer decreased with increasing duration of metformin use. Conclusion: Metformin may decrease the thyroid cancer risk in patients with acromegaly.

Source

Publisher

Churchill Livingstone

Citation

item.page.haspartof

Source

Growth Hormone and Lgf Research

item.page.ispartofseries

item.page.edition

DOI

10.1016/j.ghir.2022.101484

item.page.datauri

item.page.link

Rights

N/A

Copyrights Note

Rights and licensing

N/A

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Item type:Goal, Access status: Open Access ,
03 - Good Health and Well-being
Over the last 15 years, the number of childhood deaths has been cut in half. This proves that it is possible to win the fight against almost every disease. Still, we are spending an astonishing amount of money and resources on treating illnesses that are surprisingly easy to prevent. The new goal for worldwide Good Health promotes healthy lifestyles, preventive measures and modern, efficient healthcare for everyone.
Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators